Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

Deals > All

Total search results: 10605 | Ordered by Date (descending)
1 2 3 ... 105 106 107  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
Lead Pharma–LifeSpring: public relations, 202011 service existent by LifeSpring Communications 2020-11-16
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties 2020-11-16
Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi 2020-11-13
Handl Therapeutics–UCB: investment, 202011 acquisition of Handl Therapeutics by UCB 2020-11-12
m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences 2020-11-12
Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital 2020-11-12
Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer 2020-11-12
Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital 2020-11-12
Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund 2020-11-12
Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures 2020-11-12
Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund 2020-11-12
Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures 2020-11-12
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets 2020-11-11
Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern 2020-11-10
Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion 2020-11-10
Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund 2020-11-10
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III 2020-11-10
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III 2020-11-10
Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series 2020-11-09
Congenica–Cambridge Innovation Capital: investment, 202011 financing round Series C totalling £39m incl existing + co-investor CIC 2020-11-09
Congenica–Consilium: public relations, 202011 service existent by CSC 2020-11-09
Congenica–Downing Ventures: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Downing 2020-11-09
Congenica–IDO Investments: investment, 202011 financing round Series C totalling £39m incl new + co-investor IDO Investments 2020-11-09
Congenica–Lazard: financial services, 202011 supply service Lazard is financial advisor with regard to £39m Series C financing round 2020-11-09
Congenica–Legal & General: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Legal & General 2020-11-09
Congenica–Parkwalk Advisors: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Parkwalk 2020-11-09
Congenica–Puhua Capital: investment, 202011 financing round Series C totalling £39m incl new + co-investor Puhua Capital 2020-11-09
Congenica–SEVERAL: investment, 202011 financing round Series C £39m ($50m) co-led by Tencent + Legal & General 2020-11-09
Congenica–Tencent: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Tencent 2020-11-09
Congenica–Xeraya: investment, 202011 financing round Series C totalling £39m incl new + co-investor Xeraya 2020-11-09
Oxford Biomedica–PhoreMost: GCT discovery, 202011– collab €na using Siteseeker to find targets for CAR-T cell therapies using LentiVector technology 2020-11-09
Stargazer Pharmaceuticals–SEVERAL: investment, 202011 financing round Series A $57m with Novo Holdings + venBio + Canaan Partners + Pontifax + FFB 2020-11-09
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept 2020-11-09
Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis 2020-11-06
Cytek Biosciences–SEVERAL: investment, 202011 financing round Series D $120m co-led by RA Capital + Hillhouse Capital 2020-11-05
Galapagos–OncoArendi: chitinase inhibitors, 202011– collab + license ww developm + commerc OATD-01 €25m+€2m upfront + €295m milestones + royalties 2020-11-05
Memo Therapeutics–Bernina BioInvest: investment, 202011 financing round Series B totalling CHF14m incl new + co-investor Bernina BioInvest 2020-11-05
Memo Therapeutics–Halsin Partners: public relations, 202011 service existent by Halsin Partners 2020-11-05
Memo Therapeutics–Jaquet Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Jaquet Partners 2020-11-05
Memo Therapeutics–OTHER: investment, 202011 financing round Series B totalling CHF14m incl new private investors 2020-11-05
Memo Therapeutics–Redalpine: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Redalpine 2020-11-05
Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq 2020-11-05
Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB 2020-11-05
Memo Therapeutics–Verve Capital Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Investiere 2020-11-05
Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB 2020-11-05
VelosBio–Merck (US): investment, 202011– acquisition $2.75b in cash of VelosBio by Merck 2020-11-05
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings 2020-11-03
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures 2020-11-02
Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd 2020-11-02
Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m 2020-11-02
Horizon Discovery–PerkinElmer: investment, 202011– cash tender offer £296m ($383m) representing total enterprise value of £284m ($368m) 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
Mainstay Medical–Fountain Healthcare Partners: investment, 202011 existent investment of Fountain HP Fund III 2020-11-02
Oxford BioDynamics–Instinctif Partners: public relations, 202011 service existent by Instinctif 2020-11-02
Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC 2020-10-29
Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors 2020-10-28
Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share 2020-10-28
Eagle Genomics–ETF Partners: investment, 202010 financing round totalling $9m incl investor Environmental Technologies Fund (ETF) 2020-10-27
Eagle Genomics–Granpool Innovative Investments: investment, 202010 financing round totalling $9m incl investor consortium led by Granpool 2020-10-27
Eagle Genomics–Sarum PR: public relations, 202010 service existent Sarum PR is press contact 2020-10-27
Eagle Genomics–SEVERAL: investment, 202010 financing round $9m with ETF Partners + investor consortium led by Granpool II 2020-10-27
Kaffe Bueno–Denmark (govt): investment, 202010 seed financing round totalling €1.1m incl investor Vaekstfonden 2020-10-27
Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor 2020-10-27
Kaffe Bueno–Paulig Group: investment, 202010 seed financing round totalling €1.1m incl investor PINC 2020-10-27
Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel 2020-10-27
Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE 2020-10-27
Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) 2020-10-27
Prokarium–Korea Investment Partners: investment, 202010 financing round Series B totalling $21m led by KIP 2020-10-27
Prokarium–Riyadh Valley Company: investment, 202010 financing round Series B totalling $21m incl co-investor RVC (FF) 2020-10-27
Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners 2020-10-27
Prokarium–United Kingdom (govt): investment, 202010 financing round Series B totalling $21m incl co-investor UK Future Fund (FF) 2020-10-27
TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly 2020-10-27
TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund 2020-10-27
TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly 2020-10-27
Unilever–Eagle Genomics: microbiomics, <202010 collab use of e[datascientist] platform to support claims for enzyme-containing Zendium toothpaste 2020-10-27
AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones 2020-10-26
Base Genomics–Bristows: legal services, 202010 supply Bristows LLP legal advisor to Base Genomics for acquisition by Exact Sciences 2020-10-26
Base Genomics–Exact Sciences: investment, 202010 acquisition 100% of Base Genomics Ltd for $410m in cash (net of cash + certain other adjustments) 2020-10-26
Base Genomics–William Blair: financial services, 202010 supply William Blair financial advisor to Base Genomics for acquisition by Exact Sciences 2020-10-26
Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec 2020-10-26
Exact Sciences–K&L Gates: legal services, 202010 supply legal advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier 2020-10-26
Exact Sciences–XMS Capital: financial services, 202010 supply financial advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier 2020-10-26
MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs 2020-10-26
Scorpion Therapeutics–Abingworth: investment, 202010 financing round Series A totalling $108m incl co-investor Abingworth 2020-10-26
Scorpion Therapeutics–SEVERAL: investment, 202010 financing round Series A $108m led by Atlas Venture + Omega Funds + Vida Ventures 2020-10-26
Thrive Earlier Detection–Exact Sciences: investment, 202010– acquisition $1.7b upfront with 35% in cash + 65% common stock plus $450m milestones 2020-10-26
Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva 2020-10-20
Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market 2020-10-19
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF 2020-10-19
Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures 2020-10-19
Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital 2020-10-19
Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec 2020-10-19
Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BIoMedPartners plus all existing investors 2020-10-19
Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III 2020-10-19
NovaBiotics–Powerscourt: public relations, 202010 service existent by Powerscourt 2020-10-16
1 2 3 ... 105 106 107  next pagenext page



Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [iito] Made Without Love 650x80px

» top